Estefania P. Julia

B, Argentina

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Structural basis for sialoglycan recognition by the immune inhibitory receptor Siglec-10.

Structural basis for sialoglycan recognition by the immune inhibitory receptor Siglec-10.

Journal: Structure (London, England : 1993)

Published: May 05, 2025

Structure-guided engineering of CD112 receptor variants for optimized immunotherapy.

Structure-guided engineering of CD112 receptor variants for optimized immunotherapy.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: November 27, 2024

Phenotypic and functional analysis in HER2+ targeted therapy of human NK cell subpopulation according to the expression of FcεRIγ and NKG2C in breast cancer patients.

Phenotypic and functional analysis in HER2+ targeted therapy of human NK cell subpopulation according to the expression of FcεRIγ and NKG2C in breast cancer patients.

Journal: Cancer immunology, immunotherapy : CII

Published: February 03, 2023

Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality.

Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 13, 2022

Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer.

Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer.

Journal: Cells

Published: January 29, 2020

Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients.

Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients.

Journal: Cancer immunology, immunotherapy : CII

Published: April 02, 2019

Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.

Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.

Journal: Frontiers in immunology

Published: June 28, 2018

High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients.

High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients.

Journal: OncoTargets and therapy

Published: May 31, 2018

Early Events of the Reaction Elicited by CSF-470 Melanoma Vaccine Plus Adjuvants: An In Vitro Analysis of Immune Recruitment and Cytokine Release.

Early Events of the Reaction Elicited by CSF-470 Melanoma Vaccine Plus Adjuvants: An In Vitro Analysis of Immune Recruitment and Cytokine Release.

Journal: Frontiers in immunology

Published: July 27, 2017

Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15.

Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15.

Journal: Frontiers in immunology

Published: July 06, 2016

Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade.

Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade.

Journal: European journal of immunology

Published: November 18, 2014

Showing 1-11 of 11

Last Updated: 09/26/2026